Post date
20/11/2024
BiocSol secures €5.2M seed funding to transform sustainable crop protection with next generation microbial-based solutions, targeting total €10M in funding by year-end
- Built on decade of research
Post date
18/11/2024
ATB Therapeutics Raises €54 Million Series A Financing to Propel Innovative Antibody Payload Technology into Clinical Development
• Financing co-led by EQT Life Sciences and MRL Ventures Fund (MRLV
Post date
13/09/2024
- New investment from Luxembourg Future Fund 2 brings total funding to €75M, well above original target
- Deal underlines VIVES’ know-how in connecting academic research and innovative projects with
Post date
10/09/2024
Funding will go towards development of first long-term percutaneous right ventricular assist device
Paris, France, September 10, 2024 – Brightflow SAS, a privately held pioneer in the field of long
Post date
31/01/2024
- European Investment Fund instrumental in success of second closing
- With €38M increased funding capacity, VIVES IUF set to create ten new science-based ventures and support ten current portfolio
Post date
20/09/2023
LMO (Luxembourg & UK) and In-Space Missions Ltd (UK) have partnered to explore the use of small satellite platforms for space-based Space Domain Awareness (SDA) as part of LMO’s AUREA (Autonomous
Post date
11/07/2023
New funding will support the rapid growth of Aphea.Bio, solidifying its position as a frontrunner in biological product development for agriculture.
Gent, Belgium, 11 July 2023 – Aphea.Bio, a Belgium
Post date
19/05/2023
LMO a dual-use space company focused on space domain awareness, space surveillance and in-orbit servicing has successfully deployed and validated in space a first of a kind autonomous on-orbit
Post date
09/05/2023
Mont-Saint-Guibert, 9 th May 2023 – VOCSens unveils EnviCam® -30, its 1 st generation of multi-gas microsensor addressing the request for actionable gas concentration data in Smart Building, Chemical
Post date
09/03/2023
March 09th, Namur - Sunrise, the company revolutionising home sleep testing, announces a €17 million in funding. The successful fundraising is led by Kurma Partners and includes the exceptional entry
Post date
13/01/2023
Cellaion SA announces a total fundraising of EUR 23 million in 2022 for its phase IIB study in Acute on Chronic Liver Failure with Truffle Capital as lead investor in the final Closing followed by
Post date
08/12/2022
MONT SAINT-GUIBERT, BELGIUM – December 8, 2022 – Novadip Biosciences SA (“Novadip” or “the Company”), a clinical-stage biopharmaceutical company developing a new class of regenerative tissue products